September 11, 2017 10:17 AM EDT

AbbVie stirs safety jitters after two patients die in ABT-494 study

Arsalan Arif

Founder

AbbVie $ABBV revealed that two rheumatoid arthritis patients died in its late-stage work on ABT-494, which quickly triggered a case of the jitters for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie stirs safety jitters after two patients die in ABT-494 study

Arsalan Arif

Founder

Sign up to read this article for free.

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Beam shares results from seven patients who received gene-edited sickle cell therapy

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat

Ab­b­Vie stirs safe­ty jit­ters af­ter two pa­tients die in ABT-494 study

Arsalan Arif

Founder

Sign up to read this article for free.

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

AbbVie stirs safety jitters after two patients die in ABT-494 study

ADC scientist who paved the way for Daiichi’s Enhertu dies

AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

Beam shares results from seven patients who received gene-edited sickle cell therapy

Biosecure bill is left out of end-of-year defense package, dealing blow to chances

Dutch biotech nabs €85M to position inflammatory antibody for a pharma buyer

The key to faster, more impactful research? Put patients in the driver’s seat